Company news

ACADIA Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

August 4, 2021

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 3, 2021

The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

July 20, 2021

Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

July 20, 2021

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)

July 13, 2021

NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders

June 2, 2021

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

May 4, 2021

Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021

April 20, 2021

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

April 4, 2021

Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

March 7, 2021

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com

February 18, 2021

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 9, 2021

Acadia Pharmaceuticals Announces Commercial Leadership Change

January 26, 2021

Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

December 21, 2020

Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020

November 9, 2020

Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 3, 2020

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference

October 25, 2020

Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020

October 20, 2020

The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”

October 13, 2020

Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors

September 30, 2020

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

September 1, 2020

ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development

August 30, 2020

ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio

August 24, 2020

ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020

August 11, 2020

ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results

August 4, 2020

ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

July 21, 2020

ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

July 19, 2020

ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

June 14, 2020

ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer

May 27, 2020

ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration

May 6, 2020

ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020

April 14, 2020

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

March 2, 2020

ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer

December 17, 2019

ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

December 3, 2019

ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia

November 24, 2019

ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

November 3, 2019

ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

October 29, 2019

ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting

October 2, 2019

ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

September 23, 2019

ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 19, 2019

ACADIA Pharmaceuticals Prices Public Offering of Common Stock

September 16, 2019

ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis

September 8, 2019

ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results

July 30, 2019

ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019

April 1, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.